Partnering

Strategy

Isogenica’s strategy over the short to mid-term is to generate revenues through a programme of strategic alliances, corporate collaborations and technology out-licensing.

Isogenica wishes to form close strategic alliances with drug discovery and development companies that require new or optimised protein and peptide therapeutic leads.

In addition, the company wishes to collaborate with, or out-licence its technology to, companies working in disparate fields which may be outside of a therapeutic context.

Corporate Partners

Isogenica has completed agreements with the following companies:

Wyeth

UCB Celltech

GE Healthcare

Amgen

Neurotargets

AstraZeneca

Johnson & Johnson Pharmaceuticals

Smiths Detection

Invitrogen

Sangamo Biosciences

Affitech